Immunotherapy for Alzheimer’s Disease: DNA- and Protein-Based Epitope vacciness
Active immunotherapy for Alzheimer’s disease (AD) is aimed to induce antibodies specific to amyloid-beta (Aβ) that are capable to reduce the level of Aβ in the CNS of Alzheimer’s disease patients. First clinical trial AN-1792 that was based on vaccination with full-length Aβ42 showed that safe and effective AD vaccines should induce high titers of anti-Aβ antibodies without activation of harmful autoreactive T cells. Replacement of self-T cell epitope with foreign epitope, keeping self-B cell epitope intact, may allow to induce high titers of anti-Aβ antibodies while avoiding the activation of T cells specific to Aβ.
Source: Springer protocols feed by Immunology - Category: Allergy & Immunology Source Type: news
More News: Allergy & Immunology | Alzheimer's | Clinical Trials | Vaccines